<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Lipids Health Dis</journal-id>
<journal-title-group>
<journal-title>Lipids in Health and Disease</journal-title>
</journal-title-group>
<issn pub-type="epub">1476-511X</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30400945</article-id>
<article-id pub-id-type="pmc">6220563</article-id>
<article-id pub-id-type="publisher-id">892</article-id>
<article-id pub-id-type="doi">10.1186/s12944-018-0892-4</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prevalence of hypobetalipoproteinemia and related psychiatric characteristics in a psychiatric population: results from the retrospective <italic>HYPOPSY</italic> Study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cariou</surname>
<given-names>Bertrand</given-names>
</name>
<address>
<phone>00 33 2 53 48 27 07</phone>
<email>bertrand.cariou@univ-nantes.fr</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Challet-Bouju</surname>
<given-names>Gaëlle</given-names>
</name>
<address>
<email>gaelle.bouju@chu-nantes.fr</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bernard</surname>
<given-names>Céline</given-names>
</name>
<address>
<email>celine.bernard14@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff10">10</xref>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marrec</surname>
<given-names>Marie</given-names>
</name>
<address>
<email>marie.marrec@chu-nantes.fr</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hardouin</surname>
<given-names>Jean-Benoit</given-names>
</name>
<address>
<email>jeanbenoit.hardouin@chu-nantes.fr</email>
</address>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Authier</surname>
<given-names>Charlotte</given-names>
</name>
<address>
<email>charlotte.authier@assurance-maladie.fr</email>
</address>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bach-Ngohou</surname>
<given-names>Kalyane</given-names>
</name>
<address>
<email>kalyane.bach@chu-nantes.fr</email>
</address>
<xref ref-type="aff" rid="Aff7">7</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leux</surname>
<given-names>Christophe</given-names>
</name>
<address>
<email>christophe.leux@chu-nantes.fr</email>
</address>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pichelin</surname>
<given-names>Matthieu</given-names>
</name>
<address>
<email>matthieu.pichelin@univ-nantes.fr</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Grall-Bronnec</surname>
<given-names>Marie</given-names>
</name>
<address>
<phone>00 33 2 40 84 76 20</phone>
<email>marie.bronnec@univ-nantes.fr</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0472 0371</institution-id><institution-id institution-id-type="GRID">grid.277151.7</institution-id><institution>CHU Nantes, l’institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, </institution></institution-wrap>F-44000 Nantes, France </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0472 0371</institution-id><institution-id institution-id-type="GRID">grid.277151.7</institution-id><institution>CHU de Nantes, CIC Endocrino-Nutrition INSERM UMR 1413, l’nstitut du thorax, </institution></institution-wrap>F-44000 Nantes, France </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0472 0371</institution-id><institution-id institution-id-type="GRID">grid.277151.7</institution-id><institution>CHU Nantes, Service d’Addictologie et de Psychiatrie, </institution></institution-wrap>F-44000 Nantes, France </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.4817.a</institution-id><institution>Université de Nantes, Université de Tours, Inserm UMR 1246-SPHERE, </institution></institution-wrap>F-44000 Nantes, France </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0472 0371</institution-id><institution-id institution-id-type="GRID">grid.277151.7</institution-id><institution>CHU Nantes, DRCi, Plateforme de Méthodologie et de Biostatistique, </institution></institution-wrap>F-44000 Nantes, France </aff>
<aff id="Aff6"><label>6</label>Centre d’examens de santé de la Caisse Primaire d’Assurance Maladie de Loire-Atlantique, St Nazaire, F-44600 Saint-Nazaire, France </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0472 0371</institution-id><institution-id institution-id-type="GRID">grid.277151.7</institution-id><institution>CHU Nantes, Service de Biochimie, </institution></institution-wrap>F-44000 Nantes, France </aff>
<aff id="Aff8"><label>8</label>INSERM1235, Université de Nantes, Institut des Maladies de l’Appareil Digestif, F-44000 Nantes, France </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0472 0371</institution-id><institution-id institution-id-type="GRID">grid.277151.7</institution-id><institution>CHU Nantes, Service d’Information Médicale, </institution></institution-wrap>F-44000 Nantes, France </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0472 0371</institution-id><institution-id institution-id-type="GRID">grid.277151.7</institution-id><institution>Clinique d’Endocrinologie, Maladies Métaboliques et Nutrition, Hôpital Guillaume &amp; René Laennec, </institution></institution-wrap>Boulevard Jacques Monod, Saint-Herblain, 44093 Nantes Cedex 1, France </aff>
<aff id="Aff11"><label>11</label>Present address: CHU Sud Reunion, Site Saint-Pierre, Avenue président F Mitterrand, BP 350, 97448 ST Pierre Cedex, La Reunion France </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>6</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>6</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>17</volume>
<elocation-id>249</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2018</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">Hypobetalipoproteinemia (HBL) is defined by plasma concentrations of LDL-cholesterol (LDL-C) lower than the fifth percentile for age and sex. Several psychiatric symptoms have been reported in association with HBL. The objective was to assess the prevalence of primary HBL in patients hospitalized in a psychiatric population and to better characterize the related psychiatric disorders.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">HYPOPSY is a retrospective study including 839 adults hospitalized in the Psychiatry department of Nantes University Hospital during the year 2014, except patients with eating disorders. The prevalence of primary HBL was defined by a plasma LDL-C concentration ≤ 50 mg/dL. Secondary causes of HBL were excluded after a review of medical records (<italic>n</italic>=2). Related-psychiatric disorders in patients with and without HBL were recorded using the ICD-10 classification.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">Twenty cases of primary HBL (mean [SD] LDL-C: 42 [7] mg/dL) were diagnosed, leading to a prevalence of 2.39%. In comparison, the prevalence of HBL in a healthy control population was 0.57%. Psychiatric patients with HBL were characterized by a higher frequency of schizophrenia (<italic>p</italic>=0.044), hetero-aggression (<italic>p</italic>=0.015) and pervasive and specific developmental disorders (including autism) (<italic>p</italic>=0.011).</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par4">The prevalence of HBL is 4-fold higher in psychiatric than in general population. More specifically, some statistically significant associations were found between low LDL-C concentrations and schizophrenia, autism and hetero-aggression. These data reinforce the hypothesis for a link between genetically low LDL-C levels and psychiatric disorders.</p>
</sec>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (10.1186/s12944-018-0892-4) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Hypobetalipoproteinemia</kwd>
<kwd>LDL cholesterol</kwd>
<kwd>Autism spectrum disorders</kwd>
<kwd>Hetero-aggression</kwd>
<kwd>Schizophrenia</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>National project CHOPIN (CHolesterol Personalized Innovation), granted by the Agence Nationale de la Recherche</institution>
</funding-source>
<award-id>ANR-16-RHUS-0007</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004431</institution-id>
<institution>Fondation de France</institution>
</institution-wrap>
</funding-source>
<award-id>2014 000447967</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par17">Hypobetalipoproteinemia (HBL) is defined by plasma concentrations of LDL-cholesterol (LDL-C) or apolipoprotein B (APOB) that are lower than the fifth percentile for age and sex [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Many secondary causes, such as critical illness, lipid-lowering drugs or a strict vegan diet, can cause HBL. Familial hypobetalipoproteinemia (FHBL; OMIM#615558) is a co-dominant disorder whose frequency in the heterozygous form is estimated to be 1:1000-1:3000 [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Heterozygotes for FHBL are often asymptomatic, with plasma LDL-C levels usually between 20 and 50 mg/dL [<xref ref-type="bibr" rid="CR3">3</xref>]. FHBL has been associated with a longevity syndrome, mainly linked to cardiovascular protection. FHBL may be due to various mutations in genes affecting LDL-C metabolism: mainly <italic>APOB</italic> [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], but also <italic>PCSK9</italic> [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] or <italic>ANGPTL3</italic> [<xref ref-type="bibr" rid="CR6">6</xref>]. In approximately 50% of FHBL cases, the genetic etiology remains to be determined [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>].</p>
<p id="Par18">In a previous study aiming at identifying new genes in LDL-C metabolism, we recruited FHBL patients by screening the database of the Nantes University Hospital (HYPOCHOL study, NCT02354079) [<xref ref-type="bibr" rid="CR7">7</xref>]. We were surprised to observe that ≈ 40% of patients were coming from the Psychiatry units, which were ranked first amongst the different clinical departments, even after excluding eating disorders. The literature was discordant regarding the putative relationship between low cholesterol levels and psychiatric disorders, such as violent behavior [<xref ref-type="bibr" rid="CR8">8</xref>], suicide [<xref ref-type="bibr" rid="CR9">9</xref>], impulsivity [<xref ref-type="bibr" rid="CR10">10</xref>], autism [<xref ref-type="bibr" rid="CR11">11</xref>] or mood disorders [<xref ref-type="bibr" rid="CR12">12</xref>]. Based on this intriguing finding, we decided to conduct the HYPOPSY (HYPObetalipoproteinemia in PSYchiatric patients) study (NCT02889614). The objectives of the HYPOPSY study were to estimate the prevalence of primary HBL (defined by a plasma LDL-C concentration ≤ 50 mg/dL) in patients hospitalized in the psychiatric units of the Nantes University Hospital and to further investigate the related psychiatric disorders.</p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<sec id="Sec3">
<title>Participants</title>
<p id="Par19">The HYPOPSY study was based on a retrospective medical and biological record review, and was approved by the local Research Ethics Committee. The retrospective and non-interventional design of this study made the consent of the patients unnecessary.</p>
<p id="Par20">The flow chart of patients’ selection is presented in Fig. <xref ref-type="fig" rid="Fig1">1</xref>. To be included, participants had to be admitted in the Psychiatry department in the course of the year 2014, to be aged 18 and older, and to have had a lipid panel test (LPT). Patients admitted in the eating disorders unit were not included, because eating disorders are causes of starvation, leading to secondary HBL. Among the patients identified with a low plasma LDL-C concentration, other causes of secondary HBL were excluded by a thorough review of medical records: lipid-lowering drug treatment or low-fat diet, any cause of starvation, thalassemia or sickle-cell anemia, severe renal or pancreatic failure, decompensated liver failure and hyperthyroidism.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow chart of patients’ selection in the HYPOPSY Study</p></caption><graphic id="MO1" xlink:href="12944_2018_892_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec4">
<title>Measures</title>
<p id="Par21">For each patient included in the HYPOPSY study, a set of clinical and biological variables were systematically collected:<list list-type="order"><list-item><p id="Par22">Demographic characteristics: age, sex.</p></list-item><list-item><p id="Par23">Physical characteristics: weight, height, body mass index, current lipid-lowering drugs or low-fat diet, history of diabetes/other cardio-vascular risk factors or liver diseases.</p></list-item><list-item><p id="Par24">Psychiatric characteristics: primary diagnosis and comorbid disorders according to the ICD-10 (International Classification of Disease – 10<sup>th</sup> revision) [<xref ref-type="bibr" rid="CR13">13</xref>], history of aggressive behaviors (hetero-aggression, suicidal attempts and other self-injuries), current psychotropic drugs use, familial history of psychiatric disorders.</p></list-item><list-item><p id="Par25">Biochemical characteristics: LPT (measured plasma total cholesterol (TC), HDL-cholesterol (HDL-C) and triglycerides (TG) and calculated LDL-C according to the Friedewald formula), liver function test.</p></list-item></list></p>
</sec>
<sec id="Sec5">
<title>Statistical analysis</title>
<sec id="Sec6">
<title>Prevalence of primary HBL</title>
<p id="Par26">A case of spontaneous HBL was defined as a plasma LDL-C concentration ≤50 mg/dL. The prevalence of primary HBL was assessed by the percentage of patients with HBL among whom having a LPT and without any medical cause of secondary HBL. The prevalence of HBL in the psychiatric population was compared to the one estimated in a general non-psychiatric population from the Health Care Center (Saint-Nazaire, France) of French Health Insurance between 2012 and 2014 (control population), in the framework of the HYPOCHOL study (with the same definition of HBL).</p>
</sec>
<sec id="Sec7">
<title>Psychiatric characterization of primary HBL</title>
<p id="Par27">We considered two groups of patients (“Non-HBL” and “HBL”). An univariate analysis exploring links between the demographic, physical, psychiatric, and biological characteristics on the one hand, and the LDL-C status on the other hand, was performed using Mann-Whitney tests for the quantitative variables and Fisher tests for the qualitative variables.</p>
<p id="Par28">The statistical analysis was carried out with SAS 9.1 and R statistical software (SAS Institute, Inc.).</p>
</sec>
</sec>
</sec>
<sec id="Sec8">
<title>Results</title>
<sec id="Sec9">
<title>Prevalence of primary HBL in a psychiatric population</title>
<p id="Par29">As shown in Fig. <xref ref-type="fig" rid="Fig1">1</xref>, 839 patients were included in the study, among whom 2 were excluded due to a medical cause of secondary HBL. The prevalence of primary HBL was estimated to 2.39 % in this psychiatric population, whereas the prevalence in the control population was estimated to 0.57% (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S1).</p>
</sec>
<sec id="Sec10">
<title>Metabolic characteristics of patients with HBL</title>
<p id="Par30">The anthropometric and metabolic characteristics of the patients with and without HBL are shown in Table <xref ref-type="table" rid="Tab1">1</xref>. Patients with HBL were younger, with a lower body mass index, and had lower mean plasma TC, LDL-C and TG concentrations. Plasma lipids values were in the normal ranges in the “Non-HBL” group. There was no significant difference in the use of psychotropic drugs, including those known to interfere with lipid metabolism, between the two groups (Table <xref ref-type="table" rid="Tab1">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comparison between HBL and non-HBL groups, according to demography and main biological features (<italic>n</italic>=837)</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th>HBL<break></break>(<italic>n</italic>=20)</th><th>Non-HBL<break></break>(<italic>n</italic>=817)</th><th><italic>p</italic> - value<sup>$</sup></th></tr></thead><tbody><tr><td colspan="4">Demography</td></tr><tr><td> Age (± SD); years</td><td>35± 10</td><td>44± 14</td><td>0.0032<sup>¶</sup></td></tr><tr><td> Gender (% Male)</td><td>65%</td><td>59%</td><td>0.36</td></tr><tr><td> Weight (± SD). kg</td><td>66 ± 11</td><td>72 ± 18</td><td>0.094</td></tr><tr><td> BMI (± SD). kg/m<sup>2</sup></td><td>22 ± 4</td><td>25 ± 14</td><td>0.0115<sup>¶</sup></td></tr><tr><td colspan="4">Biological features (mg/dL)</td></tr><tr><td> TC (± SD)</td><td>123 ± 28</td><td>186 ± 40</td><td>&lt;0.0001<sup>¶</sup></td></tr><tr><td> LDL-C (± SD)</td><td>42 ± 7</td><td>109 ± 34</td><td>&lt;0.0001<sup>¶</sup></td></tr><tr><td> HDL-C (± SD)</td><td>66 ± 30</td><td>53 ± 20</td><td>0.067</td></tr><tr><td> TG (± SD)</td><td>74 ± 52</td><td>115 ± 56</td><td>&lt;0.0001<sup>¶</sup></td></tr><tr><td colspan="4">Psychotropic drugs</td></tr><tr><td> Psychotropic drug consumption</td><td>45%</td><td>60%</td><td>0.17</td></tr><tr><td> Psychotropic drug with lipid metabolism impact<sup>a</sup></td><td>25%</td><td>39%</td><td>0.25</td></tr></tbody></table><table-wrap-foot><p><sup>$</sup><italic>p</italic>-values obtained by Mann-Withney or Fisher exact tests; <italic>HDL-C</italic> high-density lipoprotein cholesterol; <italic>LDL-C</italic> low-density lipoprotein cholesterol, <italic>TC</italic> Total cholesterol, <italic>TG</italic> triglycerides</p><p><sup>a</sup>these drugs include clozapine, olanzapine, risperidone, aripiprazole, zuclopenthixol, quetiapine, paliperidone, chlopromazine</p><p><sup>¶</sup><italic>p</italic>-value &lt; 0.05</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec11">
<title>Characteristics of psychiatric disorders associated to HBL</title>
<p id="Par31">The distribution of psychiatric disorders in patients with and without HBL is shown in Table <xref ref-type="table" rid="Tab2">2</xref>. Patients with HBL were characterized by a higher frequency of “pervasive and specific developmental disorders”, especially pervasive developmental disorders. Although there was no significant difference for the global category of “schizophrenia, schizotypal and delusional disorders”, a deeper analysis conducted on each detailed diagnosis indicated that patients with HBL were also characterized by a higher frequency of schizophrenia. The comparison of aggressive behaviors in patients with and without HBL is shown in Table <xref ref-type="table" rid="Tab3">3</xref>. A higher proportion of hetero-aggression was found for patients with HBL.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Comparison between HBL and non-HBL groups, according to the primary psychiatric (ICD-10) (<italic>n</italic>=837)</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th>HBL<break></break>(<italic>n</italic>=20)</th><th>Non-HBL<break></break>(<italic>n</italic>=817)</th><th><italic>p</italic>-value</th></tr></thead><tbody><tr><td>F00-09: Organic, including symptomatic, mental disorders</td><td>0 (0%)</td><td>10 (1%)</td><td>&gt;0.99</td></tr><tr><td> F02: Dementia in other diseases</td><td>0 (0%)</td><td>2 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F03: Unspecified dementia</td><td>0 (0%)</td><td>5 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F06: Other mental disorders due to known physiological condition</td><td>0 (0%)</td><td>1 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F07: Personality and behavioral disorders due to known physiological condition</td><td>0 (0%)</td><td>1 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F09: Unspecified mental disorder due to known physiological condition</td><td>0 (0%)</td><td>1 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td>F10-19: Mental and behavioral disorders due to psychoactive substance use</td><td>4 (20%)</td><td>200 (24%)</td><td>0.79</td></tr><tr><td> F10: Alcohol related disorders</td><td>1 (5%)</td><td>126 (15%)</td><td>0.34</td></tr><tr><td> F11: Opioid related disorders</td><td>0 (0%)</td><td>3 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F12: Cannabis related disorders</td><td>1 (5%)</td><td>16 (2%)</td><td>0.33</td></tr><tr><td> F13: Sedative. hypnotic.or anxiolytic related disorders</td><td>0 (0%)</td><td>3 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F19: Other psychoactive substance related disorders</td><td>2 (10%)</td><td>53 (6%)</td><td>0.38</td></tr><tr><td>F20-29: Schizophrenia. schizotypal and delusional disorders</td><td>9 (45%)</td><td>291 (36%)</td><td>0.47</td></tr><tr><td> F20: Schizophrenia</td><td>8 (40%)</td><td>163 (20%)</td><td>0.044<sup>¶</sup></td></tr><tr><td> F21: Schizotypal disorder</td><td>0 (0%)</td><td>5 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F22: Delusional disorders</td><td>0 (0%)</td><td>34 (4%)</td><td>&gt;0.99</td></tr><tr><td> F23-24: Brief psychotic disorder / Shared psychotic disorder</td><td>0 (0%)</td><td>29 (4%)</td><td>&gt;0.99</td></tr><tr><td> F25: Schizoaffective disorder. bipolar type</td><td>1 (5%)</td><td>41 (5%)</td><td>&gt;0.99</td></tr><tr><td> F28: Other psychotic disorder not due to a substance or known physiological condition</td><td>0 (0%)</td><td>10 (1%)</td><td>&gt;0.99</td></tr><tr><td> F29: Unspecified psychosis not due to a substance or known physiological condition</td><td>0 (0%)</td><td>9 (1%)</td><td>&gt;0.99</td></tr><tr><td>F30-39: Mood [affective] disorders</td><td>3 (15%)</td><td>191 (23%)</td><td>0.59</td></tr><tr><td> F30: Manic episode</td><td>0 (0%)</td><td>17 (2%)</td><td>&gt;0.99</td></tr><tr><td> F31: Bipolar disorder</td><td>3 (15%)</td><td>81 (10%)</td><td>0.44</td></tr><tr><td> F32: Major depressive disorder. single episode</td><td>0 (0%)</td><td>68 (8%)</td><td>0.39</td></tr><tr><td> F33: Major depressive disorder. recurrent</td><td>0 (0%)</td><td>20 (2%)</td><td>&gt;0.99</td></tr><tr><td> F34: Persistent mood [affective] disorders</td><td>0 (0%)</td><td>2 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F38-39: Other mood [affective] disorders / Unspecified mood [affective] disorder</td><td>0 (0%)</td><td>4 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td>F40-48: Neurotic. stress-related and somatoform disorders</td><td>1 (5%)</td><td>83 (10%)</td><td>0.71</td></tr><tr><td> F40: Phobic anxiety disorders</td><td>0 (0%)</td><td>2 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F41: Other anxiety disorders</td><td>0 (0%)</td><td>21 (3%)</td><td>&gt;0.99</td></tr><tr><td> F43: Reaction to severe stress. and adjustment disorders</td><td>1 (5%)</td><td>52 (6%)</td><td>&gt;0.99</td></tr><tr><td> F44: Dissociative and conversion disorders</td><td>0 (0%)</td><td>5 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F48: Other nonpsychotic mental disorders</td><td>0 (0%)</td><td>3 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td>F60-69: Disorders of adult personality and behavior</td><td>1 (5%)</td><td>28 (3 %)</td><td>0.51</td></tr><tr><td> F60-61: Specific personality disorders/ mixed and other personality disorders</td><td>1 (5%)</td><td>26 (3%)</td><td>0.48</td></tr><tr><td> F66: Other sexual disorders</td><td>0 (0%)</td><td>1 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F69: Unspecified disorder of adult personality and behavior</td><td>0 (0%)</td><td>1 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F70-79: Mental retardation</td><td>0 (0%)</td><td>6 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td>F80-89: Pervasive and specific developmental disorders</td><td>2 (10%)</td><td>8 (&lt;1%)</td><td>0.022<sup>¶</sup></td></tr><tr><td> F83: Mixed specific developmental disorders</td><td>0 (0%)</td><td>1 (&lt;1%)</td><td>&gt;0.99</td></tr><tr><td> F84: Pervasive developmental disorders</td><td>2 (10%)</td><td>5 (&lt;1%)</td><td>0.011<sup>¶</sup></td></tr><tr><td> F88: Other disorders of psychological development</td><td>0 (0%)</td><td>2 (&lt;1%)</td><td>&gt;0.99</td></tr></tbody></table><table-wrap-foot><p><sup>¶</sup><italic>p</italic>-value &lt; 0.05</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Comparison between HBL and non-HBL groups, according to the history of aggressive behaviors (<italic>n</italic>=837)</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th>HBL<break></break>(<italic>n</italic>=20)</th><th>Non-HBL<break></break>(<italic>n</italic>=817)</th><th><italic>p</italic>-value<sup>*</sup></th></tr></thead><tbody><tr><td>Hetero-aggression</td><td>5 (25%)</td><td>60 (7%)</td><td>0.015<sup>¶</sup></td></tr><tr><td>Suicidal attempts (current or lifetime)</td><td>1 (5%)</td><td>60 (7%)</td><td>&gt;0.99</td></tr><tr><td>– Violent suicidal attempts</td><td>0 (0%)</td><td>17 (2%)</td><td>&gt;0.99</td></tr><tr><td>– Non-violent suicidal attempts</td><td>1 (5%)</td><td>45 (6%)</td><td>&gt;0.99</td></tr><tr><td>Other self-injuries</td><td>0 (0%)</td><td>3 (&lt;1%)</td><td>&gt;0.99</td></tr></tbody></table><table-wrap-foot><p>*<italic>p</italic>-values obtained with a Fischer exact test</p><p><sup>¶</sup><italic>p</italic>-value &lt; 0.05</p></table-wrap-foot></table-wrap></p>
</sec>
</sec>
<sec id="Sec12">
<title>Discussion</title>
<p id="Par32">We found a 4-fold higher prevalence of HBL in a psychiatric population than in a control population (2.39 vs 0.57%). HBL patients were characterized by a higher prevalence of schizophrenia and hetero-aggressive behaviors compared to control patients. In addition, while the absolute number was low (<italic>n</italic>=2), there was also a higher prevalence of pervasive developmental disorders in patients with HBL.</p>
<p id="Par33">To the best of our knowledge, this is the first time that the prevalence of HBL was specifically assessed in such a broad psychiatric population. In order to identify HBL patients, we used a LDL-C concentration ≤ 50 mg/dL as a cutoff, instead of an adjusted value of LDL-C ≤ 5<sup>th</sup> percentile for age and sex [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. We used this cutoff since FHBL patients usually have LDL-C values between 20 and 50 mg/dL [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. With these diagnosis criteria, the prevalence of HBL in the control population was 0.57%, which is moderately higher than the classically reported frequency of FHBL (1/1000 to 1/3000) [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. One striking finding was the very high frequency of HBL in patients hospitalized in Psychiatry department, with more than one patient of 50 who exhibit spontaneous low LDL-C levels. This result is in line with the report of Huang <italic>et al.</italic> that found that serum TC levels in 213 psychiatric inpatients were significantly lower than control values [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
<p id="Par34">Importantly, we carefully excluded patients under lipid-lowering drugs (mainly statins) as well as secondary causes of HBL. As it could be a potential cause of false positive results, we also verified that there was no imbalance between the use of antipsychotic drugs (with a specific focus on those interfering with lipid metabolism: clozapine, olanzapine, risperidone, aripiprazole, zuclopenthixol, quetiapine, paliperidone, chlopromazine) between patients with and without HBL. Moreover, antipsychotic medications, especially second-generation antipsychotics, are often associated with increased TG and, in a lesser extent, increased LDL-C levels but not with low LDL-C concentrations [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
<p id="Par35">We also determined that pervasive developmental disorders, schizophrenia and hetero-aggressive behaviors were more frequent among psychiatric patients with HBL. These data reinforce the hypothesis for a link between genetically low LDL-C levels and violent behavior or impulsivity.</p>
<p id="Par36">In the literature, several studies have highlighted a potential link between low cholesterol levels and violence, including hetero-aggression and suicides [<xref ref-type="bibr" rid="CR18">18</xref>]. The evidence for such association mostly derives from epidemiological and observational studies in general and violent populations. For instance, a meta-analysis of 18 epidemiological studies found 50% more violent deaths in men with TC levels less than 160 mg/dL than in subjects with higher TC levels [<xref ref-type="bibr" rid="CR19">19</xref>]. A prospective study conducted in 6393 working men followed for up to 17 years also found a 3.16 (95% CI: 1.38 to 7.22, <italic>P</italic> = 0.007) increase in relative risk of death from suicide in subjects with low average serum TC concentration (&lt; 185 mg/dL) compared with those with average serum TC concentration of 185 to 240 mg/dL [<xref ref-type="bibr" rid="CR20">20</xref>]. In addition, a study has also showed that low TC levels were associated with increased impulsivity in 301 patients referred to a psychiatric clinic [<xref ref-type="bibr" rid="CR10">10</xref>]. Old meta-analyses of randomized trials with cholesterol-lowering drugs tended to identify a trend for more violent deaths in treated <italic>vs</italic> control groups [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. However, these initial findings were not further supported in more recent trials with statins, even in those with the highest doses and thus the lowest concentrations of LDL-C [<xref ref-type="bibr" rid="CR23">23</xref>]. Very recently, no psychiatric safety signal was observed in the FOURIER cardiovascular outcomes trial with evolocumab, a PCSK9 monoclonal antibody, in which patients in evolocumab group achieved the lowest LDL-C concentration (<italic>i.e.</italic> 30 mg/dL) never reached in previous clinical studies [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p>
<p id="Par37">The literature is scarce regarding the link between FHBL and impulsive and/or violent behaviors. However, a case report of a patient with a heterozygous mutation of <italic>APOB</italic> (apoB29.4) causative of FHBL highlighted a potential association between the hypocholesterolemic status of family members and violent behavior, with an odds ratio of 16.9 [<xref ref-type="bibr" rid="CR26">26</xref>]. In the HYPOPSY study, genetic analysis was not performed in patients with HBL, thus we were unable to perform some genotype-phenotype correlations. We plan to conduct a prospective study in the same psychiatric population in which genetic analyses and family inquiries will be performed in patients with HBL in order to determine whether specific mutations in lipoprotein metabolism predispose to psychiatric disorders.</p>
<p id="Par38">Finally, some experimental studies have demonstrated an increase in violent behavior in monkeys assigned to low-cholesterol diet [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. The suspected underlying molecular mechanism is the reduction of brain serotonin transmission that has been demonstrated to be associated with increased impulsivity [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Several studies have suggested that plasma cholesterol could be a marker for central serotoninergic activity [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>] and monkeys fed with a low-cholesterol diet had lower concentrations of serotonin metabolites (5-HIAA) in their cerebrospinal fluid than monkeys on high-cholesterol diet [<xref ref-type="bibr" rid="CR28">28</xref>].</p>
<p id="Par39">In contrast to violent behaviors, there was no previously published report for a specific association between FHBL and schizophrenia. To the best of our knowledge, only the study of Atmaca <italic>et al.</italic> demonstrated that serum TC levels were lower in medication-free schizophrenic patients compared to healthy controls [<xref ref-type="bibr" rid="CR33">33</xref>], even though the number of patients was very low (<italic>n</italic>=16 for each group). However, we cannot exclude a reverse causality between schizophrenia and low LDL-C levels since a Japanese study has found that the prevalence of hypoproteinemia and hypocholesterolemia were significantly higher in schizophrenia patients than in age- and sex-matched healthy volunteers [<xref ref-type="bibr" rid="CR34">34</xref>]. Thereby, a precise nutritional status assessment will be required in the future prospective study to exclude that HBL could be linked to undernutrition in psychiatric population.</p>
<p id="Par40">Our result about the potential link between the significant association between HBL and pervasive developmental disorders has to be interpreted cautiously due the very low number of cases. Autism spectrum disorders and schizophrenia are two complex psychiatric conditions with significant heritability, and which share common phenotypic (<italic>i.e.</italic> aggressive behaviors) and endophenotypic (<italic>i.e.</italic> neurocognitive anomalies such as alterations in executive functions and social functioning) characteristics. Interestingly, a study found that 19% of children with family history of autism spectrum disorders had low TC levels (<italic>i.e.</italic> &lt; 100 mg/dL) [<xref ref-type="bibr" rid="CR11">11</xref>]. Moreover, a very recent study conducted in 23 male with Fragile-X syndrome, one of the main genetic cause of autism and intellectual deficiency, showed that these subjects had statistically significant lower levels of all lipid parameters as compared to control individuals [<xref ref-type="bibr" rid="CR35">35</xref>]. Some additional dedicated studies performed in this specific population are warranted to confirm or invalidate the association between low LDL-C levels and autism spectrum disorders.</p>
<p id="Par41">The results of our study should be interpreted in the light of several methodological limitations, which may also serve as lessons for the preparation of future works in the field. The retrospective design of the study can have introduced some bias, especially regarding the etiology of HBL. Notably, it cannot be excluded that some secondary causes of low LDL-C levels were missed (hyperthyroidism, undernutrition, etc.). In the same way, we did not have any data regarding the familial history and genetic analysis of HBL. Finally, this is a cross-sectional study and we collected only one LDL-C value to assess the prevalence of HBL. It should be interesting to have several LDL-C values, as well as APOB levels, in order to confirm FHBL diagnosis.</p>
<p id="Par42">In contrast, the strengths of this study are: i) the large size of our “real-life” cohort (&gt; 800 patients); ii) the use of a comparative control cohort in general population; iii) the precise identification of psychiatric disorders using the ICD-10 classification.</p>
<p id="Par43">However, additional prospective studies need to be conducted to confirm the higher prevalence of FHBL in the psychiatric population and to perform more extensive genotype-phenotype comparisons. Such studies are desirable regarding the safety of extremely low LDL-C levels achieved with the new classes of lipid-lowering drugs [<xref ref-type="bibr" rid="CR36">36</xref>].</p>
</sec>
<sec id="Sec13">
<title>Conclusions</title>
<p id="Par44">The HYPOPSY study found a ≈4 fold higher prevalence of HBL in patients hospitalized in Psychiatry department than in a general healthy population. More specifically, some statistically significant associations were found between low LDL-C concentrations and schizophrenia, autism and hetero-aggression. These data reinforce the hypothesis for a link between genetically low LDL-C levels and violent behavior or impulsivity. However, additional prospective studies need to be conducted in this Psychiatric population to confirm the higher prevalence of FHBL and to perform more extensive genotype-phenotype comparisons. Such studies are desirable regarding the safety of extremely low LDL-C levels achieved with the new classes of lipid-lowering drugs [<xref ref-type="bibr" rid="CR36">36</xref>]. The findings of the HYPOPSY study has served to establish power calculation, to evaluate methodological issues and to better specify which data to be collected for the preparation of a larger prospective research program named PARTITION (Prevalence of fAmilial hypobetalipopRoTeinemIa in psychiaTrIc pOpulatioN) and conducted in the framework of a larger project: the CHOPIN (CHOlesterol Personnalized Innovation) program. The PARTITION study aims at better characterizing the links between HBL and psychiatric disorders, and at evaluating a possible genotype-phenotype relationship between identified mutations and the severity of psychiatric symptoms.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Additional file</title>
<sec id="Sec14">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12944_2018_892_MOESM1_ESM.docx"><label>Additional file 1:</label><caption><p><bold>Table S1.</bold> Prevalence of HBL patients in the control population (Health care center of St Nazaire) (DOCX 22 kb)</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>APOB</term>
<def>
<p id="Par5">Apolipoprotein B</p>
</def>
</def-item>
<def-item>
<term>CHOPIN </term>
<def>
<p id="Par6">CHOlesterol Personnalized Innovation</p>
</def>
</def-item>
<def-item>
<term>FHBL</term>
<def>
<p id="Par7">Familial hypobetalipoproteinemia</p>
</def>
</def-item>
<def-item>
<term>HBL</term>
<def>
<p id="Par8">Hypobetalipoproteinemia</p>
</def>
</def-item>
<def-item>
<term>HDL-C</term>
<def>
<p id="Par9">HDL-Cholesterol</p>
</def>
</def-item>
<def-item>
<term>HYPOPSY</term>
<def>
<p id="Par10">HYPObetalipoproteinemia in PSYchiatric patients</p>
</def>
</def-item>
<def-item>
<term>ICD-10</term>
<def>
<p id="Par11">International Classification of Disease – 10<sup>th</sup> revision</p>
</def>
</def-item>
<def-item>
<term>LDL-C</term>
<def>
<p id="Par12">LDL-Cholesterol</p>
</def>
</def-item>
<def-item>
<term>LPT</term>
<def>
<p id="Par13">Lipid Panel Test</p>
</def>
</def-item>
<def-item>
<term>PARTITION</term>
<def>
<p id="Par14">Prevalence of fAmilial hypobetalipopRoTeinemIa in psychiaTrIc pOpulatioN</p>
</def>
</def-item>
<def-item>
<term>TC </term>
<def>
<p id="Par15">Total Cholesterol</p>
</def>
</def-item>
<def-item>
<term>TG</term>
<def>
<p id="Par16">Triglyceride</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgements</title>
<p>We would like to thank the heads of the Psychiatric units for their valuable assistance: Dr. Rachel Bocher, Dr. Vincent Delaunay, Dr. Hervé Inial, Dr. Wilfrid Martineau, Dr. Stéphane Prétagut, Dr. Benoit Robin.</p>
<sec id="FPar1">
<title>Funding</title>
<p id="Par45">This work was supported by the national project CHOPIN (CHolesterol Personalized Innovation), granted by the Agence Nationale de la Recherche [ANR-16-RHUS-0007] and coordinated by the CHU Nantes. The HYPOCHOL study has been granted by Fondation de France [2014 000447967].</p>
</sec>
<sec id="FPar2">
<title>Availability of data and materials</title>
<p id="Par46">All data generated or analyzed during this study are included in this published article [and its Additional files].</p>
</sec>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>Design of the study: BC, GCB, MP, MGB; Collection of the data: MM. CB, GCB, CA, KBN, CL, MGB; Statistical analysis: JBH; Biochemical analyses: KBN; Drafting the manuscript: BC, GCB, MP, MGB. All authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar3">
<title>Ethics approval and consent to participate</title>
<p>The HYPOPSY study was based on a retrospective medical and biological record review (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT02889614), and was approved by the local Research Ethics Committee on the 03/11/2015 (Groupe Nantais d’Ethique dans le Domaine de la Santé). The database has been declared to the CNIL (Commission Nationale de l'Informatique et des Libertés) – registration number: 2015-019. According to French law, the retrospective and non-interventional design of this study made the consent of the patients unnecessary.</p>
</sec>
<sec id="FPar4">
<title>Consent for publication</title>
<p>Not applicable</p>
</sec>
<sec id="FPar5">
<title>Competing interests</title>
<p>BC has received research funding from Sanofi, Regeneron and Pfizer and honoraria from Amgen, MSD (Merck &amp; Co,), Regeneron, Sanofi outside of this submitted work. The other authors have nothing to disclose.</p>
</sec>
<sec id="FPar6">
<title>Publisher’s Note</title>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarugi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Averna</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Di Leo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cefalu</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Noto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Magnolo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cattin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bertolini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Calandra</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Molecular diagnosis of hypobetalipoproteinemia: an ENID review</article-title>
<source/>Atherosclerosis.
          <year>2007</year>
<volume>195</volume>
<issue>2</issue>
<fpage>e19</fpage>
<lpage>e27</lpage>
<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2007.05.003</pub-id>
<pub-id pub-id-type="pmid">17570373</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<mixed-citation publication-type="other">Burnett JR, Bell DA, Hooper AJ, Hegele RA. Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB)--Update 2014. Eur J Hum Genet. 2015;23(6).</mixed-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linton</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Farese</surname>
<given-names>RV</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Young</surname>
<given-names>SG</given-names>
</name>
</person-group>
<article-title>Familial hypobetalipoproteinemia</article-title>
<source/>J Lipid Res.
          <year>1993</year>
<volume>34</volume>
<issue>4</issue>
<fpage>521</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="pmid">8496659</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Boerwinkle</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mosley</surname>
<given-names>TH</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Hobbs</surname>
<given-names>HH</given-names>
</name>
</person-group>
<article-title>Sequence variations in PCSK9, low LDL, and protection against coronary heart disease</article-title>
<source/>N Engl J Med.
          <year>2006</year>
<volume>354</volume>
<issue>12</issue>
<fpage>1264</fpage>
<lpage>1272</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa054013</pub-id>
<pub-id pub-id-type="pmid">16554528</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cariou</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ouguerram</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zair</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Guerois</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Langhi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kourimate</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Benoit</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Le May</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gayet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Belabbas</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia</article-title>
<source/>Arterioscler Thromb Vasc Biol.
          <year>2009</year>
<volume>29</volume>
<issue>12</issue>
<fpage>2191</fpage>
<lpage>2197</lpage>
<pub-id pub-id-type="doi">10.1161/ATVBAHA.109.194191</pub-id>
<pub-id pub-id-type="pmid">19762784</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Musunuru</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pirruccello</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Peloso</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Guiducci</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sougnez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Garimella</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Abreu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Barry</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia</article-title>
<source/>N Engl J Med
          <year>2010</year>
<volume>363</volume>
<issue>23</issue>
<fpage>2220</fpage>
<lpage>2227</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1002926</pub-id>
<pub-id pub-id-type="pmid">20942659</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rimbert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pichelin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lecointe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marrec</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Le Scouarnec</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barrak</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Croyal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krempf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Le Marec</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Redon</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia</article-title>
<source/>Atherosclerosis.
          <year>2016</year>
<volume>250</volume>
<fpage>52</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2016.04.010</pub-id>
<pub-id pub-id-type="pmid">27179706</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muldoon</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Manuck</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Mendelsohn</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Belle</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials</article-title>
<source/>BMJ.
          <year>2001</year>
<volume>322</volume>
<issue>7277</issue>
<fpage>11</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1136/bmj.322.7277.11</pub-id>
<pub-id pub-id-type="pmid">11141142</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Berardis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Piersanti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cavuto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Perna</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Valchera</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mazza</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fornaro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iasevoli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Martinotti</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Relationships between Cholesterol and Suicide: An Update</article-title>
<source/>ISRN Psychiatry.
          <year>2012</year>
<volume>387901</volume>
<fpage>2012</fpage>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Troisi</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Low cholesterol is a risk factor for attentional impulsivity in patients with mood symptoms</article-title>
<source/>Psychiatry Res.
          <year>2011</year>
<volume>188</volume>
<issue>1</issue>
<fpage>83</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2010.11.005</pub-id>
<pub-id pub-id-type="pmid">21112642</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tierney</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bukelis</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Aneja</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kratz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>RI</given-names>
</name>
</person-group>
<article-title>Abnormalities of cholesterol metabolism in autism spectrum disorders</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet.
          <year>2006</year>
<volume>141B</volume>
<issue>6</issue>
<fpage>666</fpage>
<lpage>668</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.30368</pub-id>
<pub-id pub-id-type="pmid">16874769</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papakostas</surname>
<given-names>GI</given-names>
</name>
<name>
<surname>Ongur</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Iosifescu</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Mischoulon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fava</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses</article-title>
<source/>Eur Neuropsychopharmacol.
          <year>2004</year>
<volume>14</volume>
<issue>2</issue>
<fpage>135</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="doi">10.1016/S0924-977X(03)00099-3</pub-id>
<pub-id pub-id-type="pmid">15013029</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group>
<source/>The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines
          <year>1992</year>
<publisher-loc>Geneva</publisher-loc>
<publisher-name>World Health Organization</publisher-name>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hooper</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Burnett</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Update on primary hypobetalipoproteinemia</article-title>
<source/>Curr Atheroscler Rep.
          <year>2014</year>
<volume>16</volume>
<issue>7</issue>
<fpage>423</fpage>
<pub-id pub-id-type="doi">10.1007/s11883-014-0423-3</pub-id>
<pub-id pub-id-type="pmid">24781598</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Welty</surname>
<given-names>FK</given-names>
</name>
<name>
<surname>Lahoz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tucker</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Ordovas</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<article-title>Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the framingham offspring population</article-title>
<source/>Arterioscler Thromb Vasc Biol.
          <year>1998</year>
<volume>18</volume>
<issue>11</issue>
<fpage>1745</fpage>
<lpage>1751</lpage>
<pub-id pub-id-type="doi">10.1161/01.ATV.18.11.1745</pub-id>
<pub-id pub-id-type="pmid">9812913</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Serum cholesterol levels in paranoid and non-paranoid schizophrenia associated with physical violence or suicide attempts in Taiwanese</article-title>
<source/>Psychiatry Res.
          <year>2000</year>
<volume>96</volume>
<issue>2</issue>
<fpage>175</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-1781(00)00206-7</pub-id>
<pub-id pub-id-type="pmid">11063790</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brooks</surname>
<given-names>JO</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Chang</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Krasnykh</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Metabolic risks in older adults receiving second-generation antipsychotic medication</article-title>
<source/>Curr Psychiatry Rep.
          <year>2009</year>
<volume>11</volume>
<issue>1</issue>
<fpage>33</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1007/s11920-009-0006-0</pub-id>
<pub-id pub-id-type="pmid">19187706</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Golomb</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Cholesterol and violence: is there a connection?</article-title>
<source/>Ann Intern Med.
          <year>1998</year>
<volume>128</volume>
<issue>6</issue>
<fpage>478</fpage>
<lpage>487</lpage>
<pub-id pub-id-type="doi">10.7326/0003-4819-128-6-199803150-00009</pub-id>
<pub-id pub-id-type="pmid">9499332</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobs</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Blackburn</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reed</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Iso</surname>
<given-names>H</given-names>
</name>
<name>
<surname>McMillan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Neaton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Potter</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rifkind</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Report of the Conference on Low Blood Cholesterol: Mortality Associations</article-title>
<source/>Circulation.
          <year>1992</year>
<volume>86</volume>
<issue>3</issue>
<fpage>1046</fpage>
<lpage>1060</lpage>
<pub-id pub-id-type="doi">10.1161/01.CIR.86.3.1046</pub-id>
<pub-id pub-id-type="pmid">1355411</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zureik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Courbon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ducimetière</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Serum cholesterol concentration and death from suicide in men: Paris prospective study I</article-title>
<source/>BMJ.
          <year>1996</year>
<volume>313</volume>
<issue>7058</issue>
<fpage>649</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="doi">10.1136/bmj.313.7058.649</pub-id>
<pub-id pub-id-type="pmid">8811757</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muldoon</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Manuck</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials</article-title>
<source/>BMJ.
          <year>1990</year>
<volume>301</volume>
<issue>6747</issue>
<fpage>309</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1136/bmj.301.6747.309</pub-id>
<pub-id pub-id-type="pmid">2144195</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muldoon</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Rossouw</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Manuck</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Glueck</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>PG</given-names>
</name>
</person-group>
<article-title>Low or lowered cholesterol and risk of death from suicide and trauma</article-title>
<source/>Metabolism.
          <year>1993</year>
<volume>42</volume>
<issue>9 Suppl 1</issue>
<fpage>45</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/0026-0495(93)90259-Q</pub-id>
<pub-id pub-id-type="pmid">8412786</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>LaRosa</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Kostis</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Greten</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)</article-title>
<source/>Am J Cardiol.
          <year>2007</year>
<volume>100</volume>
<issue>5</issue>
<fpage>747</fpage>
<lpage>752</lpage>
<pub-id pub-id-type="doi">10.1016/j.amjcard.2007.03.102</pub-id>
<pub-id pub-id-type="pmid">17719314</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabatine</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Giugliano</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Keech</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Honarpour</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wiviott</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Kuder</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wasserman</surname>
<given-names>SM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease</article-title>
<source/>N Engl J Med.
          <year>2017</year>
<volume>376</volume>
<issue>18</issue>
<fpage>1713</fpage>
<lpage>1722</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1615664</pub-id>
<pub-id pub-id-type="pmid">28304224</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>RP</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>De Ferrari</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Gaciong</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Ceska</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Toth</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gouni-Berthold</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lopez-Miranda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schiele</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial</article-title>
<source/>Lancet.
          <year>2017</year>
<volume>390</volume>
<issue>10106</issue>
<fpage>1962</fpage>
<lpage>1971</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(17)32290-0</pub-id>
<pub-id pub-id-type="pmid">28859947</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edgar</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Poa</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Burnett</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Violent behavior associated with hypocholesterolemia due to a novel APOB gene mutation</article-title>
<source/>Mol Psychiatry.
          <year>2007</year>
<volume>12</volume>
<issue>3</issue>
<fpage>258</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001910</pub-id>
<pub-id pub-id-type="pmid">17043676</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaplan</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Manuck</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Shively</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The effects of fat and cholesterol on social behavior in monkeys</article-title>
<source/>Psychosom Med.
          <year>1991</year>
<volume>53</volume>
<issue>6</issue>
<fpage>634</fpage>
<lpage>642</lpage>
<pub-id pub-id-type="doi">10.1097/00006842-199111000-00005</pub-id>
<pub-id pub-id-type="pmid">1758948</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaplan</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Shively</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Fontenot</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Howell</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Manuck</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Muldoon</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behavior in monkeys</article-title>
<source/>Psychosom Med
          <year>1994</year>
<volume>56</volume>
<issue>6</issue>
<fpage>479</fpage>
<lpage>484</lpage>
<pub-id pub-id-type="doi">10.1097/00006842-199411000-00001</pub-id>
<pub-id pub-id-type="pmid">7532867</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carver</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Relations of serotonin function to personality: current views and a key methodological issue</article-title>
<source/>Psychiatry Res.
          <year>2006</year>
<volume>144</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2006.03.013</pub-id>
<pub-id pub-id-type="pmid">16914207</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paaver</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nordquist</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Parik</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Harro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oreland</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Harro</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Platelet MAO activity and the 5-HTT gene promoter polymorphism are associated with impulsivity and cognitive style in visual information processing</article-title>
<source/>Psychopharmacology (Berl).
          <year>2007</year>
<volume>194</volume>
<issue>4</issue>
<fpage>545</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-007-0867-z</pub-id>
<pub-id pub-id-type="pmid">17628790</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steegmans</surname>
<given-names>P. H A</given-names>
</name>
<name>
<surname>Fekkes</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hoes</surname>
<given-names>A. W</given-names>
</name>
<name>
<surname>Bak</surname>
<given-names>A. A A</given-names>
</name>
<name>
<surname>van der Does</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Grobbee</surname>
<given-names>D. E</given-names>
</name>
</person-group>
<article-title>Low serum cholesterol concentration and serotonin metabolism in men</article-title>
<source/>BMJ
          <year>1996</year>
<volume>312</volume>
<issue>7025</issue>
<fpage>221</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1136/bmj.312.7025.221</pub-id>
<pub-id pub-id-type="pmid">8563588</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vevera</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fisar</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kvasnicka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zdenek</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Starkova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ceska</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Papezova</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission</article-title>
<source/>Psychiatry Res.
          <year>2005</year>
<volume>133</volume>
<issue>2-3</issue>
<fpage>197</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2004.11.005</pub-id>
<pub-id pub-id-type="pmid">15740995</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atmaca</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kuloglu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tezcan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ustundag</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Serum leptin and cholesterol levels in schizophrenic patients with and without suicide attempts</article-title>
<source/>Acta Psychiatr Scand.
          <year>2003</year>
<volume>108</volume>
<issue>3</issue>
<fpage>208</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="doi">10.1034/j.1600-0447.2003.00145.x</pub-id>
<pub-id pub-id-type="pmid">12890276</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sugai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fukui</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tsuneyama</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Someya</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia</article-title>
<source/>Psychiatry Clin Neurosci.
          <year>2014</year>
<volume>68</volume>
<issue>1</issue>
<fpage>78</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1111/pcn.12082</pub-id>
<pub-id pub-id-type="pmid">23992354</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Çaku</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Seidah</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Lortie</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gagne</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Perron</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dube</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Corbin</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>New insights of altered lipid profile in Fragile X Syndrome</article-title>
<source/>PLoS One.
          <year>2017</year>
<volume>12</volume>
<issue>3</issue>
<fpage>e0174301</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0174301</pub-id>
<pub-id pub-id-type="pmid">28334053</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olsson</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Angelin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Assmann</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Binder</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Bjorkhem</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Cedazo-Minguez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>von Eckardstein</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Farinaro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Muller-Wieland</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Can LDL cholesterol be too low? Possible risks of extremely low levels</article-title>
<source/>J Intern Med.
          <year>2017</year>
<volume>281</volume>
<issue>6</issue>
<fpage>534</fpage>
<lpage>553</lpage>
<pub-id pub-id-type="doi">10.1111/joim.12614</pub-id>
<pub-id pub-id-type="pmid">28295777</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>